CR20110332A - Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida - Google Patents

Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida

Info

Publication number
CR20110332A
CR20110332A CR20110332A CR20110332A CR20110332A CR 20110332 A CR20110332 A CR 20110332A CR 20110332 A CR20110332 A CR 20110332A CR 20110332 A CR20110332 A CR 20110332A CR 20110332 A CR20110332 A CR 20110332A
Authority
CR
Costa Rica
Prior art keywords
butilpiperazin
metanona
carboxamida
terc
piperazin
Prior art date
Application number
CR20110332A
Other languages
English (en)
Inventor
John Cumming
Alan Wellington Faull
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR20110332A publication Critical patent/CR20110332A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195Radicals derived from nitrogen analogues of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), los compuestos actúan a través del antagonismo del receptor CCR2b y pueden utilizarse para tratar una enfermedad inflamatoria y/o el dolor neuropático.
CR20110332A 2008-12-15 2011-06-15 Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida CR20110332A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12244508P 2008-12-15 2008-12-15

Publications (1)

Publication Number Publication Date
CR20110332A true CR20110332A (es) 2011-08-05

Family

ID=42241254

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110332A CR20110332A (es) 2008-12-15 2011-06-15 Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida

Country Status (24)

Country Link
US (3) US20100152197A1 (es)
EP (2) EP2727913A1 (es)
JP (1) JP2012512153A (es)
KR (1) KR20110099012A (es)
CN (1) CN102317273A (es)
AR (1) AR074737A1 (es)
AU (1) AU2009327575B2 (es)
BR (1) BRPI0922439A2 (es)
CA (1) CA2746990A1 (es)
CL (1) CL2011001436A1 (es)
CO (1) CO6440554A2 (es)
CR (1) CR20110332A (es)
CU (1) CU20110133A7 (es)
DO (1) DOP2011000191A (es)
EA (1) EA201190019A1 (es)
EC (1) ECSP11011131A (es)
IL (1) IL213163A0 (es)
MX (1) MX2011006087A (es)
NI (1) NI201100125A (es)
PE (1) PE20120082A1 (es)
TW (1) TW201028400A (es)
UY (1) UY32321A (es)
WO (1) WO2010071567A1 (es)
ZA (1) ZA201105219B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906645B2 (en) * 2004-12-24 2011-03-15 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
GB0525957D0 (en) * 2005-12-21 2006-02-01 Astrazeneca Ab Methods
EP3570893A1 (en) 2017-01-17 2019-11-27 GlaxoSmithKline Intellectual Property Development Ltd Non peptidic heterobivalent molecules for treating inflammatory diseases
US12319958B2 (en) 2020-07-21 2025-06-03 Rutgers, The State University Of New Jersey Method and kit for CCR2 expression profiling and disease stratification

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) * 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
US3541085A (en) * 1969-05-09 1970-11-17 American Cyanamid Co Method of preparing thiotricyclic compounds
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Vegfインヒビターとしてのキナゾリン誘導体
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
DE19743435A1 (de) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
US20060205761A1 (en) 2003-06-06 2006-09-14 Catherine Abbadie Ccr-2 antagonists for treatment of neuropathic pain
GB0428327D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Ab Method
US7906645B2 (en) 2004-12-24 2011-03-15 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
GB0525957D0 (en) * 2005-12-21 2006-02-01 Astrazeneca Ab Methods

Also Published As

Publication number Publication date
US20130289043A1 (en) 2013-10-31
CU20110133A7 (es) 2012-01-31
JP2012512153A (ja) 2012-05-31
US20120289513A1 (en) 2012-11-15
ECSP11011131A (es) 2011-07-29
MX2011006087A (es) 2011-06-21
EP2727913A1 (en) 2014-05-07
CA2746990A1 (en) 2010-06-24
AU2009327575A1 (en) 2011-06-23
WO2010071567A1 (en) 2010-06-24
BRPI0922439A2 (pt) 2017-06-06
EA201190019A1 (ru) 2012-02-28
AR074737A1 (es) 2011-02-09
EP2379519A1 (en) 2011-10-26
IL213163A0 (en) 2011-07-31
PE20120082A1 (es) 2012-03-04
TW201028400A (en) 2010-08-01
CN102317273A (zh) 2012-01-11
CO6440554A2 (es) 2012-05-15
AU2009327575B2 (en) 2013-07-04
NI201100125A (es) 2012-03-19
UY32321A (es) 2010-07-30
CL2011001436A1 (es) 2011-08-26
EP2379519A4 (en) 2012-06-20
KR20110099012A (ko) 2011-09-05
US20100152197A1 (en) 2010-06-17
DOP2011000191A (es) 2011-07-15
ZA201105219B (en) 2012-03-28

Similar Documents

Publication Publication Date Title
SV2011003884A (es) Arilpirrolidinas pesticidas
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
NI201100049A (es) Compuestos orgánicos.
UY32379A (es) Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones.
ECSP11011151A (es) Compuestos purina
DOP2012000006A (es) Agonista de gpr119
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
NI201100052A (es) Derivados de picolinamida como inhibidores de cinasa.
EA201100503A1 (ru) Глюкозидные производные и их применения
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
SV2010003472A (es) Compuestos de pirazol
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CR20110269A (es) Lactamas como inhibidores de beta secretasa
NI201100184A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5 - disustituida
CR20110332A (es) Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
EA201100502A1 (ru) Гликозидные производные и их применения
NI200900154A (es) Nuevos procedimiento de obtención de la forma cristalina v de la agomelatina
CR20110342A (es) Compuestos ciclopropilo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)